capecitabine + cisplatin + irinotecan

This is a combination chemotherapy regimen consisting of three drugs—capecitabine, cisplatin, and irinotecan. Each drug has a distinct mechanism of action targeting cancer cells: - **Capecitabine** is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and disrupts DNA synthesis in rapidly dividing cells. - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis by interfering with DNA replication and transcription. - **Irinotecan** is a topoisomerase I inhibitor; it prevents the religation of single-strand breaks during DNA replication, resulting in cell death. This combination has been investigated primarily for advanced or metastatic gastrointestinal cancers such as colorectal and gastric cancer. The regimen aims to maximize antitumor efficacy by combining agents with complementary mechanisms[1][4].